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Background: Azithromycin has been widely used for Mycoplasma genitalium treatment internationally. However, the
eradication efficacy has substantially declined recent decade. In Russia, josamycin (another macrolide) is the recommended
first-line treatment for M. genitalium infections, however, no data regarding treatment efficacy with josamycin and
resistance in M. genitalium infections have been internationally published. We examined the M. genitalium prevalence in
males attending an STI clinic in Moscow, Russia from December 2006 to January 2008, investigated treatment efficacy
with josamycin in male urethritis, and monitored the M. genitalium DNA eradication dynamics and selection of macrolide
resistance in M. genitalium during this treatment.
Methods: Microscopy and real-time PCRs were used to diagnose urethritis and non-viral STIs, respectively, in males
(n = 320). M. genitalium positive patients were treated with recommended josamycin regimen and treatment efficacy
was monitored using quantitative real-time PCR. Macrolide resistance mutations were identified using sequencing of
the 23S rRNA gene.
Results: Forty-seven (14.7%) males were positive for M. genitalium only and most (85.1%) of these had symptoms and
signs of urethritis. Forty-six (97.9%) males agreed to participate in the treatment efficacy monitoring. All the pre-treatment
M. genitalium specimens had wild-type 23S rRNA. The elimination of M. genitalium DNA was substantially faster in patients
with lower pre-treatment M. genitalium load, and the total eradication rate was 43/46 (93.5%). Of the six patients with high
pre-treatment M. genitalium load, three (50%) remained positive post-treatment and these positive specimens contained
macrolide resistance mutations in the 23S rRNA gene, i.e., A2059G (n = 2) and A2062G (n = 1).
Conclusions: M. genitalium was a frequent cause of male urethritis in Moscow, Russia. The pre-treatment M. genitalium
load might be an effective predictor of eradication efficacy with macrolides (and possibly additional antimicrobials) and
selection of macrolide resistance. Additional in vivo and in vitro data are crucial to support the recommendation of using
josamycin as first-line treatment for M. genitalium infections in Russia. It would be valuable to develop international M.
genitalium management guidelines, and quantitative diagnostic PCRs determining also M. genitalium load and resistance
mutations (for macrolides and ideally also moxifloxacin) should ideally be recommended.
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Mycoplasma genitalium has in recent decades been
shown to be a frequent cause of urethritis in men and
urethritis, cervicitis, endometritis, pelvic inflammatory
disease, and possibly infertility in women. In patients
with non-gonococcal urethritis (NGU), M. genitalium is
commonly the second most frequent etiology, i.e., after
Chlamydia trachomatis [1-6]. In the general population,
the prevalence of M. genitalium ranges from approxi-
mately 1% to 3%, and among men with symptomatic
non-chlamydial, non-gonococcal urethritis (NCNGU),
the prevalence ranges from 15% to 35% [1,7,8].
Still, no international management guidelines for M.
genitalium infections have been published. The recom-
mended treatments of male NGU in the European
guideline include tetracyclines and macrolides [9]. How-
ever, despite being effective in vitro tetracyclines have
shown a low eradication rate for M. genitalium clinically
[1,10-13]. Azithromycin 1 g single oral dose has been
widely used. However, despite that large, appropriate
randomized clinical trials are lacking an extended azi-
thromycin regimen has been indicated to be slightly
more effective or at least equally effective in eradicating
M. genitalium, i.e., azithromycin 500 mg on day 1
followed by 250 mg daily on days 2–5 [1,11,13-15].
Worryingly, the eradication rate of M. genitalium after
azithromycin 1 g therapy has substantially declined dur-
ing the last decade [1,10,12-14,16]. Recently, it was also
reported that azithromycin 1 g therapy was associated
with selection of azithromycin resistance in M. genita-
lium [14]. It was also most recently hypothesized that
treatment failure can be associated with a higher load of
M. genitalium in the clinical specimens [17]. M. genita-
lium strains resistant to azithromycin contain resistance
mutations in region V of 23S rRNA, which is encoded
be a single copy gene in M. genitalium [1,10,13,14,18].
Moxifloxacin is the most commonly used second-line
regimen in patients failing azithromycin therapy. How-
ever, the side-effects, cost, and the risk of selection of re-
sistance limit the moxifloxacin use [1,13,15,19,20].
In Russia, the 16-membered lactone ring macrolide josa-
mycin (500 mg three times daily, 10 days) is the nationally
recommended first-line treatment for M. genitalium infec-
tions and it is widely used mainly in the treatment of NGU,
C. trachomatis infections and M. genitalium infections, in-
cluding in pregnancy [21]. Josamycin is also included in the
second-line treatment in the European C. trachomatisman-
agement guideline [22], however, in general josamycin is
very rarely used in the majority of European countries. Des-
pite that the in vitro susceptibility to josamycin in M.
hominis and ureaplasmas are high [23,24], very limited
in vitro data regarding josamycin susceptibility in M.
genitalium have been published [25], which have not in-
dicated a higher activity than azithromycin. Furthermore,no data regarding treatment efficacy of M. genitalium
infections with josamycin have been published in the
international (English language) literature. Moxifloxacin
400 mg daily, 10 days can be used as a second-line regi-
men for treatment of M. genitalium infections in Russia.
The aims of this study were to examine the prevalence
of M. genitalium in males attending an STI clinic in
Moscow, Russia from December 2006 to January 2008,
investigate the treatment efficacy with josamycin in male
urethritis, and to monitor the M. genitalium DNA eradi-
cation dynamics and selection of macrolide resistance in
M. genitalium during treatment of male urethritis with
josamycin.Methods
The work was performed at the Department of Molecular
Diagnostics and Epidemiology, Central Research Institute
for Epidemiology, Moscow, Russia.Study population
Consecutive males (n = 320) attending one of the ven-
ereologist at a sexually transmitted infection (STI) clinic
in Moscow, Russia, from December 2006 to January
2008, were enrolled in the study. The males attended the
STI clinic due to urethral symptoms or having had un-
protected sexual intercourse with new or multiple con-
tact(s). The mean age of the males was 31 years (median
age: 30 years; range: 18 to 66 years). All males signed an
informed consent form, the males were clinically exam-
ined and two urethral swabs were sampled from each
patient, i.e. for microscopy and PCR, respectively.Ethical approval
Ethical approval for the study was obtained by the Central
Research Institute for Epidemiology, Moscow, Russia.Laboratory diagnostics (microscopy and PCR)
Microscopy (1000× magnification) of Gram-stained
smears was performed. The presence of ≥5 polymorpho-
nuclear leucocytes (PMNL) per high power field (hpf), in
at least 5 hpf, was interpreted as urethritis. For diagnosis,
M. genitalium DNA was detected by the real-time PCR
assay AmpliSens® M.genitalium-FRT, and the AmpliSens®
N.gonorrhoeae-FRT, AmpliSens® C.trachomatis-FRT, and
AmpliSens® T.vaginalis-FRT assays (InterLabServices Ltd,
Moscow, Russia) were used to diagnose other non-viral
STIs. The DNA isolation and PCR assays, which have
been previously evaluated, were performed in accord-
ance with the instructions from the manufacturer
(InterLabServices Ltd, Moscow, Russia) and as previ-
ously described [26-29].
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In accordance with the Russian treatment guidelines, all M.
genitalium positive patients were treated with josamycin
500 mg three times daily, 10 days [21]. Treatment fail-
ures with the josamycin regimen were administered
moxifloxacin 400 mg daily, 10 days. Patients positive for
any other STI (according to the laboratory test results)
were also treated in accordance with the Russian treat-
ment guidelines [21].
Monitoring of josamycin treatment efficacy
All M. genitalium positive patients that did not have any
other STI, any complicated urogenital infection, or had
been administered any antimicrobials in four weeks
prior to enrollment, were invited for monitoring of treat-
ment efficacy. In participating patients, one urethral
swab (for microscopy) and one first-void urine specimen
(for PCR) were sampled, in a standardized and quality
assured manner, on treatment onset, 3rd and 8th day of
treatment, and 2nd and 14th days after completed treat-
ment. The first-void urine was collected in 50 mL sterile
disposable plastic containers, with a calibration scale in
mL on the wall of the container. According to instruc-
tions and using these containers, the patients collected
15–20 mL of first-void urine (predominantly morning
urine and the patients should not had urinated 3 h be-
fore). Valid data regarding the time since last micturition
was unfortunately not possible to obtain. At each visit,
compliance of the therapy was ensured. To quantify the
M. genitalium load in these clinical specimens, three in
house prepared DNA calibrators based on the gyrB gene
(102, 103, 104 genome equivalents (geq)/reaction) were
included in the real-time PCR assay AmpliSens® M.geni-
talium-FRT (InterLabService Ltd, Moscow, Russia) [26].
The M. genitalium concentration detected was expressed
as number of geq [log10] per 1 mL of transport media and
the M. genitalium load in each specimen was arbitrarilyTable 1 Symptoms/signs, polymorphonuclear leucocytes (PMN









Symptoms/signs and 222 75 40
PMNLs ≥5
Symptoms/signs and 0 0 0
PMNLs <5
No symptoms/signs and 49 27 6
PMNLs ≥5
No symptoms/signs and 49 8 5
PMNLs <5
Total 320 110 51
aFour patients positive for M. genitalium as well as some additional STI etiological a
type 2 (n = 1), were excluded.categorized as low (≤4 geq/mL [log10]), moderate (>4 - <6
geq/mL [log10]) or high (≥6 geq/mL [log10]). The M.
genitalium positive samples were subsequently pre-
served at −70°C, that is, prior to sequencing for identifi-
cation of macrolide resistance mutations.
Identification of macrolide resistance mutations
For identification of macrolide resistance mutations, domain
V of the 23S rRNA gene in M. genitalium was sequenced
using the previously described primers Mg23S-1992F and
Mg23S-2138R [18].
Results
Symptoms/signs, microscopy results and STI etiological
agents in all males (n = 320)
Among the 320 males, 222 (69.4%) had symptoms/signs
and microscopically confirmed urethritis, and 49 (15.3%)
had no symptoms/signs but microscopically verified ureth-
ritis (Table 1). Accordingly, in total 271 cases of urethritis
were confirmed. C. trachomatis, M. genitalium, Neisseria
gonorrhoeae and Trichomonas vaginalis was detected in
102 (37.6%), 46 (17.0%), 29 (10.7%) and 9 (3.3%), respect-
ively, of the 271 urethritis cases. C. trachomatis and M.
genitalium was also detected in eight and five, respectively,
of the males lacking symptoms/signs and having ≤5
PMNLs/hpf.
Mycoplasma genitalium positive males
In total, M. genitalium was detected in 51 (15.9%) of the
320 includes males. However, four of the M. genitalium
positive males were also positive for some additional STI
etiological agent, that is, C. trachomatis (n = 2), T. vagi-
nalis (n = 1), and Herpes simplex virus type 2 (n = 1).
For the treatment monitoring, these four males were ex-
cluded. However, no males were excluded due to having a
complicated urogenital infection or taking antimicrobials













gent, i.e. C. trachomatis (n = 2), T. vaginalis (n = 1), and Herpes simplex virus
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lium only, which corresponded to 44 (16.2%) of the con-
firmed 271 urethritis cases. Of these 47M. genitalium
positive patients, 40 (85.1%) had symptoms of urethritis
and ≥5 PMNL/hpf, four (8.5%) were asymptomatic but
had ≥5 PMNL/hpf, and three (6.4%) had no symptoms
and <5 PMNL/hpf. Twenty-two (46.8%) and 15 (31.9%) of
the 47 patients had ≥10 and >50 PMNL/hpf, respectively.
Monitoring of treatment efficacy with josamycin
Forty-six (97.9%) of the 47 males positive for only M.
genitalium agreed to participate and attended most of
the visits for the monitoring of treatment efficacy with
josamycin. The mean age of these participants was
30 years (median age: 30 years; range: 18 to 41 years).
The results of the treatment monitoring are summarized
in Table 2.
Briefly, 10 (22.2%), 29 (64.4%) and six (13.3%) of the pa-
tients had a low (≤4 geq/mL [log10]), moderate (>4 - <6
geq/mL [log10]) and high (≥6 geq/mL [log10]), respectively,
pre-treatment M. genitalium load. All the available pre-
treatment M. genitalium specimens (n = 45) had a wild-
type 23S rRNA gene sequence. After only three days of
treatment, 48.9% (22/45) of the examined patients were
M. genitalium negative, and after eight days of treatment
88.9% (40/45) were negative. The elimination of M. genita-
lium DNA was substantially faster in patients with lower
pre-treatment M. genitalium load. For example, all the 13
(100%) patients with low pre-treatment bacterial load were
M. genitalium negative already after three days of treat-
ment, and only 6.9% (2/29) of patients with moderate pre-
treatment M. genitalium load had detectable levels of M.
genitalium DNA two days post-treatment, which was
eliminated 10–14 days post-treatment. However, of the six
patients with high pre-treatment M. genitalium load three
(50%) remained positive 10–14 days after completed treat-
ment (Table 2). All these three patients repeatedly assured







Low ≤4 10 (100)
Moderate >4 - <6 29 (100)
High ≥6 6 (100)
Total no. of patients examined 45a
geq/mL (log10), log10 of genome equivalents/mL; d/t, days of treatment; d/at, days
aSample from one patient was not available. At 3 d/t, this patient had 3.1 geq/mL [
bSample from one patient was not available. This patient was asymptomatic, M. gen
subsequent visits.
cSample from one patient was not available. This was treatment failure A, see Table
dSample from one patient was not available. The patient reported to be asymptom
DNA was detected.
eThirty-two patients did not attend. However, all of the non-attending patients were
also reported to be completely asymptomatic on phone.sexual contacts between initiation of josamycin therapy
and follow up visit 10–14 days after completed treatment.
Accordingly, the eradication rate with the josamycin treat-
ment was 43/46 (93.5%). Details regarding the three treat-
ment failures are provided in Table 3.
Treatment failures with josamycin (n = 3)
Briefly, at the time of diagnosis two of the three patients
had severe symptoms of urethritis and high number of
PMNL/hpf, however, the remaining patient was asymp-
tomatic with <5 PMNL/hpf. In the two symptomatic pa-
tients, the symptoms and signs initially resolved.
However, one of them had relapsed symptoms and signs
of severe urethritis 10–14 days after treatment, which
was also the case for the initially asymptomatic patient.
The M. genitalium strains in all three patients had muta-
tions in the macrolide resistance region of 23S rRNA
during treatment. Accordingly, the M. genitalium strains
in two and one of those patients had an A2059G muta-
tion (Escherichia coli numbering) and A2062G mutation,
respectively, in the 23S rRNA gene (Table 3). The pa-
tients were subsequently successfully treated with moxi-
floxacin 400 mg daily, 10 days.
Discussion
In the present study, it was shown that M. genitalium is a
frequent cause of male urethritis in Moscow, Russia and
that the M. genitalium eradication rate in 2006-2008 was
93.5% with the recommended first-line treatment in
Russia, that is, josamycin 500 mg three times daily, 10 days
[21]. These are the first data published regarding efficacy
using josamycin for treatment of M. genitalium infections
in the international (English language) literature. Accord-
ingly, no evidence-based data supporting josamycin, com-
pared to e.g. azithromycin, for treatment of M. genitalium
infections and exceedingly limited in vitro data regarding
josamycin susceptibility in M. genitalium, have been inter-
nationally published. To our best knowledge, the onlyatment with josamycin in 46 males with urethritis
f M. genitalium positive patients
3 d/t 8 d/t 2 d/at 10-14 d/at
3 (30) 0 (0) 0 (0) 0 (0)
15 (51.7)b 3 (10.3) 2 (6.9)d 0 (0)
5 (83.3) 2 (33.3)c 3 (50) 3 (50)
45 45 45 14e
after completed treatment.
log10], and at the three subsequent visits he was M. genitalium negative.
italium negative but demonstrated microscopic signs of urethritis on the three
3.
atic on the phone and at 3 d/t and 8 d/t, no symptoms, signs or M. genitalium
M. genitalium negative already at earlier visits (both at 8 d/t and 2 d/at) and
Table 3 Details of three failures to treat Mycoplasma genitalium urethritis with josamycin, including bacterial load in
log10 genome equivalents/mL (23S rRNA gene), symptoms and microscopy results at different visits
Patients Sexual orientation 0 d/t 3 d/t 8 d/t 2 d/at 10-14 d/at







































d/t, days of treatment; d/at, days after completed therapy; WT, wild-type 23S rRNA gene sequence; NA, not assessed (specimen not available and too low concentration
of M. genitalium DNA for 23S rRNA gene sequencing, respectively); PMNL/hpf, polymorphonuclear leucocytes/high power field.
aAll three patients repeatedly reassured that they had not had any unprotected sexual contacts between initiation of the josamycin treatment and test of cure. All
patients were subsequently successfully treated with moxifloxacin 400 mg single oral dose daily in 10 days, which was confirmed by lack of symptoms, signs and
M. genitalium DNA at follow up visit four weeks after the treatment.
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1992 (only seven isolates were tested) and the activity was
slightly lower compared to azithromycin [25]. In the
present study, it was also shown that josamycin resistance
resulting in treatment failures can rapidly be selected dur-
ing treatment. The eradication rate of M. genitalium after
the internationally widely used azithromycin 1 g therapy
has substantially declined during the last decade
[1,10,12-14,16]. Treatment with azithromycin 1 g was also
recently associated with selection of macrolide resistant
M. genitalium [14], and it was also hypothesized that
treatment failures are frequently associated with a higher
load of M. genitalium [17]. The results of the present
study, instead examining the macrolide josamycin, are in
full concordance with these recent findings. Accordingly,
three failures to treat male M. genitalium urethritis
with josamycin were verified. All of these patients had
a high pre-treatment M. genitalium load (>6 geq/mL
[log10]) and M. genitalium cells with mutations in the
macrolide resistance-determining region V of 23S
rRNA [1,10,13,14,18] were selected during treatment.
Thus, despite that no 23S rRNA gene mutations were
identified in the pre-treatment M. genitalium speci-
mens the term selected resistance instead of induced
resistance was used in the present study. Accordingly,
it was considered that an undetected minority popula-
tion of macrolide resistant M. genitalium cells might
have been present already pre-treatment. These resist-
ant cells, in the specimens with high M. genitalium
load, could subsequently be selected during treatment
with the bacteriostatic josamycin. The probability of
this selection scenario was considered higher particu-
larly because it is unknown how frequently josamycin
might be able to directly induce 23S rRNA genemutations, especially during treatment of M. genita-
lium with a very long generation time. The three iden-
tified treatment failures were further supported by the
rebound in M. genitalium loads in all three patients
and the recrudescence of symptoms in two of the three
patients. Thus, the pre-treatment M. genitalium load
might be an effective predictor of eradication efficacy with
macrolides (and possibly additional antimicrobials) and se-
lection of macrolide resistance due to mutations in the
23S rRNA gene. Unambiguously, additional data are cru-
cial to support the recommendation of using josamycin
regimen as first-line treatment in the Russian treatment
guidelines for M. genitalium infections.
The most frequent 23S rRNA mutations identified in
M. genitalium strains resistant to the 15-membered
macrolide azithromycin have been A2058G and A2059G
[1,13,14,17,18,30,31]. In the present study, it was for the
first time shown that the A2059G mutation is associated
also with M. genitalium resistance to 16-membered
macrolides, e.g. josamycin. It has been earlier demon-
strated that the A2059G mutation results in high-level
resistance to 16-membered macrolides in the closely re-
lated species M. pneumoniae [32]. The A2062G muta-
tion found in the remaining treatment failure has not
been previously described in M. genitalium. However,
M. hominis and M. pneumoniae cells with A2062G and
A2062T mutations in the 23S rRNA gene have been pre-
viously selected in vitro using josamycin and shown to
cause high-level josamycin resistance [33,34]. Interest-
ingly, previous studies have suggested that mutations in the
A2062 position of the 23S rRNA gene result in resistance
to the 16-membered macrolides (e.g., josamycin), but not
necessarily to the 15-membered macrolides (e.g., azithro-
mycin), indicating a slightly different binding site [35-37].
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in vitro exposure of josamycin, has also been shown to sig-
nificantly increase the MICs of the streptogramin pristina-
mycin [34]. This is of grave concern because pristinamycin
is highly active against M. genitalium infections and cur-
rently the only treatment option for infections resistant to
both azithromycin and moxifloxacin [38]. Nevertheless, it
remains unknown if an A2058G/A2059G mutation (result-
ing in azithromycin resistance) and an A2062G mutation
(resulting in resistance to pristinamycin (and josamycin))
can co-exist in the 23S rRNA gene of M. genitalium, i.e.
without severely decreasing the biological fitness and
possibilities for transmission of the M. genitalium
strain.
Conclusions
In the present study, it was shown that M. genitalium is a
frequent cause of male urethritis in Moscow, Russia. Fur-
thermore, the first data on efficacy using josamycin for
treatment of M. genitalium urethritis were also presented
(93.5% eradication rate). All the three verified treatment
failures had a high pre-treatment M. genitalium load and
cells with mutations in the macrolide resistance region of
23S rRNA were easily selected during treatment. Because
the present study examined material from December 2006
to January 2008 and the population selective pressure for
resistance due to wide usage of macrolides has been very
large and selected for relatively high-levels of azithromycin
resistance in many countries during the recent decade, it
is crucial to examine the josamycin treatment efficacy and
M. genitalium load, including cut-off for possible treat-
ment failure, as well as to screen for resistance to macro-
lides (and other antimicrobials) in a more recent material
of M. genitalium positive clinical specimens (pre- and
post-treatment) in Russia. This should ideally include
both genetic screening for macrolide resistance muta-
tions (previously described and novel), moxifloxacin re-
sistance mutations and culture of M. genitalium,
including MIC determination for macrolides (including
azithromycin and josamycin), moxifloxacin and pristi-
namycin to confirm the phenotypic effects of the muta-
tions on the antimicrobial resistance. No evidence-based
data supporting josamycin, compared to e.g. azithromycin,
for treatment of M. genitalium infections and exceedingly
limited in vitro data regarding josamycin susceptibility in
M. genitalium, have been internationally published [25].
Accordingly, additional in vivo and in vitro data are crucial
to support the currently recommended josamycin regimen
as first-line treatment in the Russian treatment guidelines
for M. genitalium infections. It would be valuable to de-
velop and implement international guidelines for manage-
ment of M. genitalium infections and the results of the
present study indicate that quantitative diagnostic PCRs
determining also M. genitalium load and resistancemutations (for macrolides and ideally also moxifloxacin)
should ideally be recommended for diagnosis ofM. genita-
lium infections. Finally, novel options for effective treat-
ment of M. genitalium infections are essential and dual
antimicrobial therapy, which has been introduced for gon-
orrhoea, might need to be considered also for M. genita-
lium infections.
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